166 related articles for article (PubMed ID: 24486204)
21. Structure and catalytic mechanism of the human histone methyltransferase SET7/9.
Xiao B; Jing C; Wilson JR; Walker PA; Vasisht N; Kelly G; Howell S; Taylor IA; Blackburn GM; Gamblin SJ
Nature; 2003 Feb; 421(6923):652-6. PubMed ID: 12540855
[TBL] [Abstract][Full Text] [Related]
22. A continuous protein methyltransferase (G9a) assay for enzyme activity measurement and inhibitor screening.
Dhayalan A; Dimitrova E; Rathert P; Jeltsch A
J Biomol Screen; 2009 Oct; 14(9):1129-33. PubMed ID: 19734436
[TBL] [Abstract][Full Text] [Related]
23. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
[TBL] [Abstract][Full Text] [Related]
24. A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors.
Quinn AM; Allali-Hassani A; Vedadi M; Simeonov A
Mol Biosyst; 2010 May; 6(5):782-8. PubMed ID: 20567762
[TBL] [Abstract][Full Text] [Related]
25. Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.
Kashyap S; Sandler J; Peters U; Martinez EJ; Kapoor TM
Bioorg Med Chem; 2014 Apr; 22(7):2253-60. PubMed ID: 24650704
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of product specificity of AdoMet methylation catalyzed by lysine methyltransferases: transcriptional factor p53 methylation by histone lysine methyltransferase SET7/9.
Zhang X; Bruice TC
Biochemistry; 2008 Mar; 47(9):2743-8. PubMed ID: 18260647
[TBL] [Abstract][Full Text] [Related]
27. Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study.
Ramya Chandar Charles M; Hsieh HP; Selvaraj Coumar M
J Biomol Struct Dyn; 2019 Jul; 37(10):2581-2592. PubMed ID: 30047835
[TBL] [Abstract][Full Text] [Related]
28. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
29. Biochemical Assay Development for Histone Methyltransferases Using a Transcreener-Based Assay for S-Adenosylhomocysteine.
Kumar M; Zielinski T; Lowery RG
Assay Drug Dev Technol; 2015 May; 13(4):200-9. PubMed ID: 25710335
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors.
Mai A; Valente S; Cheng D; Perrone A; Ragno R; Simeoni S; Sbardella G; Brosch G; Nebbioso A; Conte M; Altucci L; Bedford MT
ChemMedChem; 2007 Jul; 2(7):987-91. PubMed ID: 17458842
[No Abstract] [Full Text] [Related]
31. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
[TBL] [Abstract][Full Text] [Related]
32. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.
Tachibana M; Matsumura Y; Fukuda M; Kimura H; Shinkai Y
EMBO J; 2008 Oct; 27(20):2681-90. PubMed ID: 18818694
[TBL] [Abstract][Full Text] [Related]
33. Methylation-acetylation interplay activates p53 in response to DNA damage.
Ivanov GS; Ivanova T; Kurash J; Ivanov A; Chuikov S; Gizatullin F; Herrera-Medina EM; Rauscher F; Reinberg D; Barlev NA
Mol Cell Biol; 2007 Oct; 27(19):6756-69. PubMed ID: 17646389
[TBL] [Abstract][Full Text] [Related]
34. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of histone H3K9 methyltransferases by gliotoxin and related epipolythiodioxopiperazines.
Takahashi M; Takemoto Y; Shimazu T; Kawasaki H; Tachibana M; Shinkai Y; Takagi M; Shin-ya K; Igarashi Y; Ito A; Yoshida M
J Antibiot (Tokyo); 2012 May; 65(5):263-5. PubMed ID: 22334240
[No Abstract] [Full Text] [Related]
36. The future therapeutic potential of histone demethylases: A critical analysis.
Natoli G; Testa G; De Santa F
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of substrate methylation and inhibition of SMYD2.
Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
[TBL] [Abstract][Full Text] [Related]
38. Specificity of protein lysine methyltransferases and methods for detection of lysine methylation of non-histone proteins.
Rathert P; Dhayalan A; Ma H; Jeltsch A
Mol Biosyst; 2008 Dec; 4(12):1186-90. PubMed ID: 19396382
[TBL] [Abstract][Full Text] [Related]
39. Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity.
Martinez NJ; Simeonov A
Drug Discov Today Technol; 2015 Nov; 18():9-17. PubMed ID: 26723887
[TBL] [Abstract][Full Text] [Related]
40. Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.
Mozzetta C; Pontis J; Ait-Si-Ali S
Antioxid Redox Signal; 2015 Jun; 22(16):1365-81. PubMed ID: 25365549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
